Daehan Pharm makes the basic medicines that hospitals and clinics use to treat patients, with intravenous (IV) fluids that replenish water and electrolytes, ampoule products, and nutritional IV solutions at its core; it has also broadened into over-the-counter items such as lens-cleaning solution. Because IV fluids are an essential consumable for hospitals, demand is steady and relatively insulated from the economic cycle. In 2025 the company posted revenue of about ₩207.9 billion, and in the first quarter it recorded ₩52.7 billion in revenue, ₩7.9 billion in operating profit, and ₩7.0 billion in net profit, with a dividend yield of roughly 4.1% that is on the high side. The point to watch lately is that if costs stabilize and profits turn upward again, the double-digit margins, a 9.2% ROE, light debt, a low P/E that sits below book value, and the 4%-plus dividend would strongly highlight how undervalued the stock is; but if the recent dip in operating profit and the pause in margins drags on, the stock could stay cheap for longer.
At-a-glance assessment financial health · growth · profitability · valuation
- Debt ratio, current ratio and interest burden all look healthy.
- Revenue rose 2.2% year over year, and the pace is slowing (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 5.7% higher than a year earlier.
- ROE is 9.2% (total-net basis). It is above the sector average.
- Operating margin is 14.9%.
- The forward P/E sits below the sector median.
Ownership & governance As of 2025-12-31
Largest shareholder Lee Yoon-woo 24.41% (individual)
Controlling bloc incl. related parties 39.4%
With the controlling bloc holding 39%, the ownership structure is stable.
🔎 In-depth analysis
- Daehan Pharm makes the basic medicines that hospitals and clinics use to treat patients.
- Its mainstays are intravenous (IV) fluids and ampoule products that replenish the body's water and electrolytes, along with nutritional IV solutions that supply nutrition to patients who cannot eat.
- On top of this, it has widened its sales reach into OTC products (over-the-counter medicines bought without a doctor's prescription) that consumers buy at pharmacies, such as lens-cleaning solution and multipurpose sodium-chloride solution.
- The foundation of this business is that IV fluids are an essential consumable hospitals use every day, so demand is steady and not heavily swayed by the economic cycle.
- The latest closing price is ₩25,500 and market capitalization is ₩153.0 billion.
- The price sits below its 20-day line (₩25,632) and its 60-day line (₩27,121).
- Trading below both the short- and mid-term moving averages, the trend is on the subdued side.
- The RSI (a supplementary gauge that weighs upward versus downward momentum over the past 14 days on a 0-100 scale) is 45.3, a neutral level.
- The one-month change is -2.5%, the three-month change is -10.2%, and the position versus the 52-week high is -24.3%.
- Relative strength versus the KOSDAQ is 70 (1-99, computed from returns against the index over the past year with recent performance weighted more heavily; higher means stronger than the market).
- That places it in roughly the top 29% of all stocks by strength.
- Over the past three months it outpaced the index by 22.0%.
- Chart reading is best done alongside trading volume and disclosure dates.
- Recent annual revenue is ₩208.6 billion, operating profit ₩31.2 billion, and net profit ₩27.6 billion, for a double-digit operating margin of 14.9% and net margin of 13.3%.
- ROE (how much the company earns in a year on its equity) is 9.2%, above the peer average.
- On the balance sheet, a debt ratio of 115.8%, a current ratio of 364%, and an interest coverage ratio of 124x mean the debt burden is light and short-term liquidity is ample.
- The trailing (most recent confirmed results) P/E is 5.29x and P/B is 0.49x; a P/B below 1x means the stock is priced below the company's book net assets.
- These figures are not high enough to be a burden — on the contrary, they show the price is set low relative to earnings and assets.
- Revenue rose each year, from ₩195.9 billion in 2023 to ₩204.2 billion in 2024 and ₩208.6 billion in 2025, a gentle upward slope.
- First-quarter 2026 revenue was ₩52.7 billion, up 5.7% from a year earlier, so top-line growth is holding, and the forward P/E reflecting this quarter's trend and the annual trajectory is 5.73x.
- That said, 2025 operating profit fell from the prior year on cost and expense factors, and first-quarter operating profit also declined year over year, so revenue is rising but the pace of profit growth is pausing for a moment.
- In other words, the demand base is stable while margin recovery is the point to watch going forward.
- If profits revive again, it could turn out that today's low P/E did not fully reflect that value.
- In February 2026 the company declared a cash and in-kind dividend, continuing its shareholder returns, with a dividend yield of about 4.1% that is on the high side.
- In March it disclosed the 2025 annual report (revenue of about ₩207.9 billion), and in May the first-quarter 2026 report (revenue ₩52.7 billion, operating profit ₩7.9 billion, net profit ₩7.0 billion).
- It is best to check whether quarterly results point in the same direction as the annual trend and whether any one-off factors are mixed in.
- For the dividend, the key to sustainability is whether earnings strength and cash flow support it.
- The strengths are clear.
- With IV fluids, an essential consumable, the company generates steady revenue that is less swayed by the economy; it has double-digit margins, a 9.2% ROE, light debt, and ample liquidity; and the stock trades below book value at the lowest P/E among its peers, with a 4%-plus dividend added on top — an undervalued zone.
- The point to be careful about is that while the top line is growing, recent operating profit has fallen and margins are taking a breather.
- If costs stabilize and profits turn upward again, it becomes a strong picture supported by low valuation and the dividend; conversely, if the margin slowdown drags on, the stock could stay cheap for longer.
- Ultimately, whether the margin recovers is the key condition that decides this stock's strength or weakness.
🔎 Valuation vs peers Undervalued
A comparison set of pharmaceutical and bio names with adjacent market capitalization.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Jeil Pharmaceutical | 6.40x | 0.71x | 11.08% |
| CMG Pharma | — | 0.64x | -5.00% |
| Samil Pharmaceutical | — | 0.99x | -26.01% |
Within pharmaceuticals and bio, we prioritized a public-data comparison set with nearby market capitalization. The current P/E (how many times a year's earnings the price represents) is 5.53x and P/B (how many times book value the price represents) is 0.51x. That said, for smaller-cap names, earnings swings and financing disclosures carry a large effect, so we did not draw firm conclusions from last year's confirmed-results metrics alone. The basis for the outlook box is a DART seasonality approximation.
Earnings outlook company-stated · verified
| Type | Period | Revenue | Operating profit | Net profit |
|---|---|---|---|---|
| This year | 2026 | ₩221.3 billion | ₩29.0 billion | ₩26.9 billion |
| Next quarter | Q2 2026 | ₩54.6 billion | ₩7.0 billion | ₩6.5 billion |
Price history Close · MA20 · MA60
The latest close is ₩25,500 and the market capitalization is ₩153.0 billion. The price sits below its 20-day moving average (₩25,632) and below its 60-day moving average (₩27,121). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 45.3, a neutral level. The one-month change is -2.5%, the three-month change is -10.2%, and the position relative to the 52-week high is -24.3%. Relative strength versus the KOSDAQ is 70 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 71% of all stocks. Over the past three months it outpaced the index by 22.0%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M +21.96% / 6M +8.30% / 12M -19.12%
Key metrics vs sector median
Valuation
The P/E of 5.53x is below the sector median (15.98x). The P/B of 0.51x is below the sector median (1.37x). Both metrics are low versus peers, so the price is not expensive relative to earnings and assets.
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is 9.2%, above the sector average (3.0%). The operating margin is 14.9%. The debt ratio is 115.8%, so the financial structure is moderate.
Growth FY2025 · annual report (separate)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $129.8M | $135.3M | $138.3M | +2.16% ↓ slower |
| Operating profit | $23.7M | $25.2M | $20.7M | -18.11% ↓ slower |
| Net profit | $18.8M | $22.4M | $18.3M | -18.11% ↓ slower |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $113.6M | $122.1M | $129.8M | $135.3M | $138.3M |
| Operating profit | $19.3M | $21.9M | $23.7M | $25.2M | $20.7M |
| Net profit | $15.0M | $16.5M | $18.8M | $22.4M | $18.3M |
| Revenue CAGR | 4-yr avg 5.03% | ||||
Revenue rose 2.2% year over year (2023 ₩195.9 billion → 2024 ₩204.2 billion → 2025 ₩208.6 billion), and the three-year trend is 'rising'. That said, the pace of growth slowed from the prior year. Operating profit fell 18.1% year over year. The decline widened. Over the 5 years on record, revenue compound annual growth (CAGR) is 5.0%. The two-year revenue CAGR is 3.2%. In the most recent quarter (Q1 2026), revenue was 5.7% higher than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- P/E and P/B are both low versus peers, so the price looks inexpensive relative to earnings and assets.
- The dividend yield, at 3.9%, is on the high side.
- The balance sheet is stable in terms of debt and liquidity.
Points to watch
- Revenue rose 2.2% year over year, and the pace is slowing (3-year trend: rising).
Recent news & events searched · sourced
- 2026-02-11UpdateCash and in-kind dividend decision: check the return termsA disclosure related to cash returns or a change in share count. Check whether earnings strength and cash flow support it. Source
- 2026-05-15EarningsQuarterly report (2026.03): Q1 2026 revenue ₩52.7 billion, operating profit ₩7.9 billion, net profit ₩7.0 billionRecent confirmed or preliminary results. Check whether it points the same direction as the annual trend and whether any one-off factors are present. Source
- 2026-03-18EarningsAnnual report (2025.12): revenue ₩207.9 billion, operating profit ₩30,000, net profit ₩30,000Recent confirmed or preliminary results. Check whether it points the same direction as the annual trend and whether any one-off factors are present. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Closing price | ₩25,500 | ₩25,500 | Confirmed | link |
| Latest quarterly results | revenue ₩52.7 billion, operating profit ₩7.9 billion | revenue ₩52.7 billion, operating profit ₩7.9 billion | Confirmed | link |
| Annual results | revenue ₩208.6 billion, operating profit ₩31.2 billion | revenue ₩208.6 billion, operating profit ₩31.2 billion | Confirmed | link |
| Shareholder-return disclosure text | ㆍ: | ㆍ: | Confirmed | link |
| Results disclosure text | (2026.03): 2026 1 revenue ₩52.7 billion · operating profit ₩7.9 billion · net profit ₩7.0 billion | (2026.03): 2026 1 revenue ₩52.7 billion · operating profit ₩7.9 billion · net profit ₩7.0 billion | Confirmed | link |
| Results disclosure text | (2025.12): revenue ₩207.9 billion · operating profit 3 · net profit 3 | (2025.12): revenue ₩207.9 billion · operating profit 3 · net profit 3 | Confirmed | link |
| Outlook-box basis | DART | DART | Confirmed | link |
Recent filings
- 2026-06-05OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-28OwnershipOwnership-change filing
- 2026-05-28OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-22OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-15PeriodicQuarterly report
- 2026-03-26Shareholders' meeting notice
- 2026-03-18PeriodicAnnual business report
- 2026-03-18Audit report
- 2026-03-06Disclosure
- 2026-03-06Shareholders' meeting notice
- 2026-02-25Shareholders' meeting notice
- 2026-02-11DividendCash/stock dividend decision
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.